Am J Epidemiol

1. REIFEIS SA, Hudgens MG, Troester MA, Love MI, et al
   Assessing etiological heterogeneity for multinomial outcome with two-phase outcome-dependent sampling design.
   Am J Epidemiol. 2025;194:1072-1078.
   

   >> Share

   
   

   
   Ann Oncol

2. PAPAKONSTANTINOU A, Foukakis T
   Neoadjuvant treatment of HER2-positive breast cancer: Has the era of antibody-drug conjugates arrived?
   Ann Oncol. 2025 Apr 5:S0923-7534(25)00133-4. doi: 10.1016/j.annonc.2025.
   

   >> Share

   
   

   
   Ann Surg

3. JOGERST K, Gupta N, Kosiorek HE, Lee YS, et al
   Reducing Chronic Opioid Use: Long-term Impacts of Enhanced Recovery After Mastectomy Protocols.
   Ann Surg. 2025;281:787-795.
   

   >> Share

   
   

   
   Ann Surg Oncol

4. DENNIS S, Tsukioki T, Kocherginsky M, Qi AK, et al
   Neoadjuvant Chemotherapy Response and Genetic Susceptibility in Recently Parous Women with Breast Cancer: A Retrospective Analysis.
   Ann Surg Oncol. 2025 Apr 9. doi: 10.1245/s10434-025-17204.
   

   >> Share

   
   

   
   BMC Cancer

5. WANG G, Wang S, Song W, Lu C, et al
   Integrating multi-omics data reveals the antitumor role and clinical benefits of gamma-delta T cells in triple-negative breast cancer.
   BMC Cancer. 2025;25:623.
   

   >> Share

   
   
6. WANG S, Guo J, Xian X, Li M, et al
   Correction: Distinct 5-methylcytosine profiles of LncRNA in breast cancer brain metastasis.
   BMC Cancer. 2025;25:625.
   

   >> Share

   
   
7. TARAPARA B, Shah F
   Role of MRE11 in DNA damage repair pathway dynamics and its diagnostic and prognostic significance in hereditary breast and ovarian cancer.
   BMC Cancer. 2025;25:650.
   

   >> Share

   
   
8. CARVALHO MM, Bah A, Azrib S, Hiatt RA, et al
   Evaluation of performance indicators of a national breast cancer screening program in Casablanca, Morocco.
   BMC Cancer. 2025;25:612.
   

   >> Share

   
   
9. ANDO Y, Miyadera H, Bando H, Hashimoto S, et al
   HLA class II-restricted T cell epitopes in public neoantigens of ESR1 and PIK3CA in breast cancer.
   BMC Cancer. 2025;25:610.
   

   >> Share

   
   
10. AKHLAQI M, Ghofrani A, Najdi N, Ranjkesh M, et al
    A systematic review and meta-analysis of pregnancy-associated breast cancer incidence rate.
    BMC Cancer. 2025;25:660.
    

    >> Share

    
    

    
    Br J Cancer

11. PETERS J, van Leeuwen MM, Moriakov N, van Dijck JAAM, et al
    Development of radiomics-based models on mammograms with mass lesions to predict prognostically relevant characteristics of invasive breast cancer in a screening cohort.
    Br J Cancer. 2025 Apr 6. doi: 10.1038/s41416-025-02995.
    

    >> Share

    
    

    
    Breast Cancer

12. NAGAI SE, Hattori M, Yoshinami T, Masuda H, et al
    Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2- advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study).
    Breast Cancer. 2025 Apr 5. doi: 10.1007/s12282-025-01689.
    

    >> Share

    
    
13. MIZUTA M, Okumura M, Inoue J, Ueda Y, et al
    Association between preoperative grip strength and postoperative upper extremity impairments in patients with breast cancer: a retrospective cohort study.
    Breast Cancer. 2025 Apr 10. doi: 10.1007/s12282-025-01699.
    

    >> Share

    
    
14. WATANUKI R, Sakai H, Takehara Y, Yoshida A, et al
    Risk factors for early recurrence in patients with hormone receptor-positive, HER2-negative breast cancer: a retrospective cohort study in Japan (WJOG15721B).
    Breast Cancer. 2025 Apr 10. doi: 10.1007/s12282-025-01700.
    

    >> Share

    
    
15. JO A, Iwamoto T, Suzuki Y, Ogata R, et al
    Validation of the Symptom Illustration Scale within an electronic Patient-Reported Outcomes Monitoring environment for metastatic breast cancer patients undergoing chemotherapy.
    Breast Cancer. 2025 Apr 10. doi: 10.1007/s12282-025-01702.
    

    >> Share

    
    
16. DING X, Zhu M, Kan H, Wang Q, et al
    Relationship between psychological resilience and cognitive function on breast cancer chemotherapy patients: a person-centered method.
    Breast Cancer. 2025 Apr 10. doi: 10.1007/s12282-025-01697.
    

    >> Share

    
    
17. MAN V, Duan J, Luk WP, Fung LH, et al
    Different strategies in de-escalation of axillary surgery in node-positive breast cancer following neoadjuvant treatment: a systematic review and meta-analysis of long-term outcomes.
    Breast Cancer. 2025 Apr 5. doi: 10.1007/s12282-025-01692.
    

    >> Share

    
    

    
    Breast Cancer Res

18. YAGHJYAN L, Heng YJ, Sardella BR, Murthy D, et al
    Associations of circulating insulin-like growth factor-1 and insulin-like growth factor binding protein-3 with the expression of stem cell markers in benign breast tissue.
    Breast Cancer Res. 2025;27:53.
    

    >> Share

    
    
19. HAN J, Zhai X, Tao X, Li Y, et al
    Pharmacovigilance study of adverse reactions of anti-HER-2 drugs for the treatment of HER-2-positive breast cancer based on the FAERS database.
    Breast Cancer Res. 2025;27:54.
    

    >> Share

    
    

    
    Breast Cancer Res Treat

20. HIDAKA K, Goto-Yamaguchi L, Sueta A, Tomiguchi M, et al
    Identifying gene expression predictive of response to neoadjuvant endocrine therapy in early breast cancer.
    Breast Cancer Res Treat. 2025 Apr 9. doi: 10.1007/s10549-025-07693.
    

    >> Share

    
    
21. DIAO B, Cai Y, Song D, Hu Y, et al
    A potential therapeutic molecule target: lncRNA AK023507 inhibits the metastasis of breast cancer by regulating the WNT/DOCK4/beta-catenin axis.
    Breast Cancer Res Treat. 2025 Apr 9. doi: 10.1007/s10549-025-07695.
    

    >> Share

    
    
22. CHIEN YN, Lin LY, Lin YC, Hsieh YC, et al
    Correction: Taxane/anthracycline combinations reduced incidence of breast cancer recurrence in young women across molecular subtypes: a real-world evidence of Taiwan from 2011 to 2019.
    Breast Cancer Res Treat. 2025 Apr 10. doi: 10.1007/s10549-025-07691.
    

    >> Share

    
    
23. TURKOGLU E, Akdag Topal G, Yildirim S, Kinikoglu O, et al
    Comparison of paclitaxel and docetaxel in dual HER2 blockade: efficacy and safety in neoadjuvant treatment of HER2-positive breast cancer.
    Breast Cancer Res Treat. 2025 Apr 11. doi: 10.1007/s10549-025-07694.
    

    >> Share

    
    

    
    Breast J

24. DESAI A, Kesmodel SB, Susnik B, Goel N, et al
    Florid Lobular Carcinoma In Situ: Imaging Characteristics and Pathologic Upgrade Rates on Surgical Excision.
    Breast J. 2025;2025:3580992.
    

    >> Share

    
    

    
    Cancer

25. ZEINOMAR N, Perlstein M, Qin B, Iyer HS, et al
    Associations between experiences of discrimination and quality of life in Black breast cancer survivors.
    Cancer. 2025;131:e35836.
    

    >> Share

    
    

    
    Cancer Epidemiol Biomarkers Prev

26. VERDIESEN RMG, Shokouhi M, Burgess S, Canisius S, et al
    Causal effects of breast cancer risk factors across hormone receptor breast cancer subtypes: A two-sample Mendelian randomization study.
    Cancer Epidemiol Biomarkers Prev. 2025.
    

    >> Share

    
    

    
    Cancer Lett

27. KUNDU M, Greer YE, Lobanov A, Ridnour L, et al
    TRAIL induces cytokine production via the NFkB2 pathway promoting neutrophil chemotaxis and neutrophil-mediated immune-suppression in triple negative breast cancer cells.
    Cancer Lett. 2025;620:217692.
    

    >> Share

    
    

    
    Clin Breast Cancer

28. KAHRAMAN S, Erul E, Gumusay O, Guven DC, et al
    Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic?Breast Cancer: Turkish Oncology Group (TOG) Study.
    Clin Breast Cancer. 2025 Mar 4:S1526-8209(25)00049.
    

    >> Share

    
    
29. KULKARNI SE, Patel SA, Jiang C, Schwieger L, et al
    Postmastectomy Radiation Therapy for Intermediate-Risk Breast Cancer Patients With 0-3 Positive Axillary Lymph Nodes: Emulating the SUPREMO Trial Using Real-World Data.
    Clin Breast Cancer. 2025 Mar 11:S1526-8209(25)00066.
    

    >> Share

    
    

    
    Clin Exp Metastasis

30. LIANG H, Yin G, Feng D, Shi G, et al
    Ras-proximate-1 (RAP1): a prognosis and therapeutic target in the metastatic spread of breast cancer.
    Clin Exp Metastasis. 2025;42:23.
    

    >> Share

    
    

    
    Eur J Cancer

31. BEDARD PL, Jhaveri KL, Accordino MK, Cervantes PA, et al
    Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study.
    Eur J Cancer. 2025;221:115397.
    

    >> Share

    
    
32. MIYAWAKI IA, Banerjee I, Batalini F, Campello Jorge CA, et al
    Global disparities in artificial intelligence-based mammogram interpretation for breast cancer: A scientometric analysis of representation, trends, and equity.
    Eur J Cancer. 2025;220:115394.
    

    >> Share

    
    

    
    Eur J Surg Oncol

33. ZHANG W
    Comment on "Long-term outcome for neoadjuvant versus adjuvant chemotherapy in early breast cancer and the prognostic impact of nodal therapy response: A population-based study".
    Eur J Surg Oncol. 2025;51:110002.
    

    >> Share

    
    

    
    Eur Radiol

34. XIA S, Hua Q, Song Y, Yuan C, et al
    Super-resolution ultrasound imaging of intranodal lymphatic sinuses for predicting sentinel lymph node metastasis in breast cancer: a preliminary study.
    Eur Radiol. 2025 Apr 5. doi: 10.1007/s00330-025-11520.
    

    >> Share

    
    

    
    Exp Cell Res

35. KHAZAEI-POUL Y, Firouzjaei AA, Paryan M, Tafti A, et al
    Evaluation of the Impact of miR-3143 on the PI3K/AKT Signaling Pathway and Its Subsequent Influence on the Metastatic Phenotype of Triple-Negative Breast Cancer Cells.
    Exp Cell Res. 2025 Apr 7:114552. doi: 10.1016/j.yexcr.2025.114552.
    

    >> Share

    
    

    
    Int J Cancer

36. GARCIA-SAENZ JA, Spera G, Pollan M, Bermejo B, et al
    Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studi
    Int J Cancer. 2025 Apr 10. doi: 10.1002/ijc.35432.
    

    >> Share

    
    

    
    J Biol Chem

37. SENDANAYAKE LR, Pokhrel R, Holub JM
    Surveying helix 12 dynamics within constitutively active estrogen receptors using bipartite tetracysteine display.
    J Biol Chem. 2025;301:108231.
    

    >> Share

    
    
38. -M FAN TW, Yan J, Goncalves CFL, Islam JMM, et al
    Patient-derived organotypic tissue cultures as a platform to evaluate metabolic reprogramming in breast cancer patients.
    J Biol Chem. 2025 Apr 8:108495. doi: 10.1016/j.jbc.2025.108495.
    

    >> Share

    
    

    
    J Clin Oncol

39. PARK KU, Somerfield MR, Anne N, Brackstone M, et al
    Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update.
    J Clin Oncol. 2025 Apr 10:JCO2500099. doi: 10.1200/JCO-25-00099.
    

    >> Share

    
    
40. YAMAMOTO Y, Iwata H, Saji S, Takahashi M, et al
    Erratum: Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis.
    J Clin Oncol. 2025 Apr 11:JCO2500722. doi: 10.1200/JCO-25-00722.
    

    >> Share

    
    
41. CHOONG GM, Hoskin TL, Boughey JC, Ingle JN, et al
    Endocrine Therapy Omission in Estrogen Receptor-Low (1%-10%) Early-Stage Breast Cancer.
    J Clin Oncol. 2025 Apr 11:JCO2402263. doi: 10.1200/JCO-24-02263.
    

    >> Share

    
    
42. WINCHESTER DJ, Singh L, Edge SB, Allison KH, et al
    Novel Postneoadjuvant Prognostic Breast Cancer Staging System.
    J Clin Oncol. 2025 Apr 11:JCO2401739. doi: 10.1200/JCO-24-01739.
    

    >> Share

    
    

    
    J Natl Cancer Inst

43. HAMMARSTROM M, Gabrielson M, Bergqvist J, Lundholm C, et al
    Influence of endoxifen on mammographic density: results from the KARISMA-Tam trial.
    J Natl Cancer Inst. 2025;117:629-636.
    

    >> Share

    
    
44. STROOT IAS, Bart J, Hollema H, Wagner MM, et al
    High-grade serous carcinoma occurring after risk-reducing salpingo-oophorectomy in BRCA1/2 germline pathogenic variant carriers.
    J Natl Cancer Inst. 2025;117:719-727.
    

    >> Share

    
    
45. LI S, Madanat-Harjuoja L, Leslie G, Barnes DR, et al
    Childhood, adolescent, and young adulthood cancer risk in BRCA1 or BRCA2 pathogenic variant carriers.
    J Natl Cancer Inst. 2025;117:728-736.
    

    >> Share

    
    
46. BARGON CA, Mink van der Molen DR, Young-Afat DA, Batenburg MCT, et al
    Clinical and patient-reported outcomes after oncoplastic vs conventional breast-conserving surgery-a longitudinal, multicenter cohort study.
    J Natl Cancer Inst. 2025;117:781-789.
    

    >> Share

    
    
47. ZHANG J, Zhang L, Liu Z, Jia Y, et al
    RE: Endocrine therapy and risk of cardiovascular disease and mortality in postmenopausal breast cancer survivors.
    J Natl Cancer Inst. 2025 Apr 9:djaf093. doi: 10.1093.
    

    >> Share

    
    

    
    Mod Pathol

48. ABUBAKAR M, Fan S, Klein A, Pfeiffer RM, et al
    Spatially-resolved Single-cell Morphometry of Benign Breast Disease Biopsy Images Uncovers Quantitative Cytomorphometric Features Predictive of Subsequent Invasive Breast Cancer Risk.
    Mod Pathol. 2025 Apr 8:100767. doi: 10.1016/j.modpat.2025.100767.
    

    >> Share

    
    

    
    Mol Ther Oncol

49. AL HASHAMI ZS, van der Vegt B, Mourits MJE, Kluiver J, et al
    miRNA-dependent resistance mechanisms to anti-hormonal therapies in estrogen receptor-positive breast cancer patients.
    Mol Ther Oncol. 2025;33:200941.
    

    >> Share

    
    
50. REN H, Liu S, Ji D, Li X, et al
    Transcriptome analysis reveals the potential role of neural factor EN1 for long-terms survival in estrogen receptor-independent breast cancer.
    Mol Ther Oncol. 2025;33:200965.
    

    >> Share

    
    
51. TANG X, Jiang N, Kou Y, Cheng S, et al
    PLA2G4F is a metabolic checkpoint in triple-negative breast cancer: Insights from multiple omics analysis and experiments.
    Mol Ther Oncol. 2025;33:200963.
    

    >> Share

    
    

    
    Oncogene

52. MUGISHA S, Baba SA, Labhsetwar S, Dave D, et al
    S100A8/A9 innate immune signaling as a distinct mechanism driving progression of smoking-related breast cancers.
    Oncogene. 2025;44:1051-1062.
    

    >> Share

    
    
53. GUO Z, Dong RW, Wu Y, Dong S, et al
    Cyclin-dependent kinase 4 and 6 inhibitors in breast cancer treatment.
    Oncogene. 2025 Apr 8. doi: 10.1038/s41388-025-03378.
    

    >> Share

    
    

    
    PLoS One

54. GODINA C, Khazaei S, Belting M, Vallon-Christersson J, et al
    Correction: High Caveolin-1 mRNA expression in triple-negative breast cancer is associated with an aggressive tumor microenvironment, chemoresistance, and poor clinical outcome.
    PLoS One. 2025;20:e0322403.
    

    >> Share

    
    

    
    Proc Natl Acad Sci U S A

55. ZHAO X, Zhao Y, Li Z, Liu H, et al
    Proximity-activated DNA scanning encoded sequencing for massive access to membrane proteins nanoscale organization.
    Proc Natl Acad Sci U S A. 2025;122:e2425000122.
    

    >> Share

    
    

    
    Radiol Imaging Cancer

56. SU Y, Qiu Y, Huang X, Peng Y, et al
    Benign and Malignant Breast Lesions: Differentiation Using Microstructural Metrics Derived from Time-Dependent Diffusion MRI.
    Radiol Imaging Cancer. 2025;7:e240287.
    

    >> Share

    
    

    
    Radiologia (Engl Ed)

57. GRANA-LOPEZ L, Abelairas-Lopez L, Villares A
    Cryoablation in breast tumours.
    Radiologia (Engl Ed). 2025;67:214-222.
    

    >> Share

    
    

    
    Radiology

58. HA SM, Lee JM, Jang MJ, Kim HK, et al
    Breast Cancer Detection with Standalone AI versus Radiologist Interpretation of Unilateral Surveillance Mammography after Mastectomy.
    Radiology. 2025;315:e242955.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share